Novo Nordisk A/S vs TotalEnergies SE — how do they compare? Novo Nordisk A/S trades at $46.12 (market cap $207.85B), while TotalEnergies SE trades at $87.19 (market cap $196.06B). The key difference: Novo Nordisk A/S and TotalEnergies SE are close in size by market cap, and TotalEnergies SE pays the higher dividend (4.82%). Which is the better fit depends on your goals.
| NVO | TTE | |
|---|---|---|
Market Cap | $207.85B | $196.06B |
Sector | Health | Energy |
52-Week High | $63.98 | $93.60 |
52-Week Low | $35.29 | $57.39 |
Enterprise Value | $222.55B | $227.06B |
Dividend Yield | 3.81% | 4.82% |
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
TotalEnergies SE (TTE) trades at $87.96, up 2.48% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while the company expands in renewables and gas projects. Valuation ratios like P/E of 11.01 and P/S of 0.98 appear attractive relative to sector peers.
The outlook is positive given strategic acquisitions and gas field developments, but risks include revenue declines and legal challenges. With a consensus price target of $94.00 and 57.58% buy ratings, the stock offers upside potential amid energy transition opportunities.
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →